Diagnosis and treatment of autoimmune pancreatitis

doi:10.3877/cma.j.issn.2095-3232.2024.04.009

Abstract

Abstract:

Autoimmune pancreatitis (AIP) is a special type of pancreatitis. Due to low clinical incidence and different epidemiological characteristics among regions, no consensus has been reached regarding the understanding of diagnosis and treatment of AIP. Due to lack of specific clinical symptoms, it is difficult to make an early diagnosis and the misdiagnosis rate is relatively high. In this article, based on recent guidelines on the diagnosis and treatment of AIP combined with clinical experience, research progress in the diagnosis and treatment of AIP was reviewed and analyzed, aiming to provide reference for improving the overall cure rate of AIP.

Key words: Autoimmune pancreatitis, Chronic pancreatitis, Pancreatic carcinoma, Diagnosis, Treatment

Tianfu Wang, Gang Wang. Diagnosis and treatment of autoimmune pancreatitis[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(04): 492-497.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2024.04.009

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2024/V13/I04/492

References 36

[1]	Yoshida K, Toki F, Takeuchi T, et al. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis[J]. Dig Dis Sci, 1995, 40(7):1561-1568.
[2]	Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology[J]. Pancreas, 2011, 40(3):352-358.
[3]	王刚, 丁乙轩, 孙备, 等. 自身免疫性胰腺炎21例临床分析[J]. 中华外科杂志, 2015, 53(9):680-684.
[4]	丁乙轩, 白雪巍, 王刚, 等. 自身免疫性胰腺炎的研究进展[J]. 中华肝胆外科杂志, 2014, 20(11):837-840.
[5]	吴丹, 邱秋, 唐亮, 等. 2009年至2018年我国自身免疫性胰腺炎患者临床特征分析[J]. 中华胰腺病杂志, 2020, 20(5):368-372.
[6]	Fukuda S, Akiyama S, Tarakji A, et al. Prevalence and clinical features of patients with autoimmune pancreatitis and inflammatory bowel disease: a systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2022, 37(8):1474-1484.
[7]	Nista EC, de Lucia SS, Manilla V, et al. Autoimmune pancreatitis: from pathogenesis to treatment[J]. Int J Mol Sci, 2022, 23(20):12667.
[8]	Song TJ, Kim MH, Moon SH, et al. The combined measurement of total serum IgG and IgG4 may increase diagnostic sensitivity for autoimmune pancreatitis without sacrificing specificity, compared with IgG4 alone[J]. Am J Gastroenterol, 2010, 105(7):1655-1660.
[9]	Chang MC, Liang PC, Jan S, et al. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels[J]. Pancreatology, 2014, 14(5):366-372.
[10]	Jia H, Li J, Huang W, et al. Multimodel magnetic resonance imaging of mass-forming autoimmune pancreatitis: differential diagnosis with pancreatic ductal adenocarcinoma[J]. BMC Med Imaging, 2021, 21(1):149.
[11]	Ogawa H, Takehara Y, Naganawa S. Imaging diagnosis of autoimmune pancreatitis: computed tomography and magnetic resonance imaging[J]. J Med Ultrason, 2021, 48(4):565-571.
[12]	Ha J, Choi SH, Kim KW, et al. MRI features for differentiation of autoimmune pancreatitis from pancreatic ductal adenocarcinoma: a systematic review and meta-analysis[J]. Dig Liver Dis, 2022, 54(7):849-856.
[13]	Choi SY, Kim SH, Kang TW, et al. Differentiating mass-forming autoimmune pancreatitis from pancreatic ductal adenocarcinoma on the basis of contrast-enhanced MRI and DWI findings[J]. AJR Am J Roentgenol, 2016, 206(2):291-300.
[14]	Tang CYL, Chua WM, Cheng LTJ, et al. 18F-FDG PET/CT manifestations of IgG4-related disease[J]. Br J Radiol, 2021, 94(1124):20210105.
[15]	Ohtani M, Ofuji K, Akazawa Y, et al. Clinical usefulness of[18F]-fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography for distinguishing between autoimmune pancreatitis and pancreatic cancer[J]. Pancreas, 2021, 50(7):1014-1019.
[16]	Sandrasegaran K, Menias CO. Imaging in autoimmune pancreatitis and immunoglobulin G4-related disease of the abdomen[J]. Gastroenterol Clin North Am, 2018, 47(3):603-619.
[17]	Guo T, Xu T, Zhang S, et al. The role of EUS in diagnosing focal autoimmune pancreatitis and differentiating it from pancreatic cancer[J]. Endosc Ultrasound, 2021, 10(4):280-287.
[18]	Cho MK, Moon SH, Song TJ, et al. Contrast-enhanced endoscopic ultrasound for differentially diagnosing autoimmune pancreatitis and pancreatic cancer[J]. Gut Liver, 2018, 12(5):591-596.
[19]	Okazaki K, Kawa S, Kamisawa T, et al. Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2020[J].J Gastroenterol, 2022, 57(4):225-245.
[20]	Kanno A, Masamune A, Fujishima F, et al. Diagnosis of autoimmune pancreatitis by EUS-guided FNA using a 22-gauge needle: a prospective multicenter study[J]. Gastrointest Endosc, 2016, 84(5):797-804, e1.
[21]	Morishima T, Kawashima H, Ohno E, et al. Prospective multicenter study on the usefulness of EUS-guided FNA biopsy for the diagnosis of autoimmune pancreatitis[J]. Gastrointest Endosc, 2016, 84(2):241-248.
[22]	Facciorusso A, Barresi L, Cannizzaro R, et al. Diagnostic yield of endoscopic ultrasound-guided tissue acquisition in autoimmune pancreatitis: a systematic review and meta-analysis[J]. Endosc Int Open, 2021, 9(1):E66-75.
[23]	Ishikawa T, Kawashima H, Ohno E, et al. Usefulness of endoscopic ultrasound-guided fine-needle biopsy for the diagnosis of autoimmune pancreatitis using a 22-gauge Franseen needle: a prospective multicenter study[J]. Endoscopy, 2020, 52(11):978-985.
[24]	Okazaki K, Chari ST, Frulloni L, et al. International consensus for the treatment of autoimmune pancreatitis[J]. Pancreatology, 2017, 17(1):1-6.
[25]	Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease[J]. Arthritis Rheumatol, 2015, 67(7):1688-1699.
[26]	Hart PA, Topazian MD, Witzig TE, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience[J]. Gut, 2013, 62(11):1607-1615.
[27]	Tacelli M, Celsa C, Magro B, et al. Risk factors for rate of relapse and effects of steroid maintenance therapy in patients with autoimmune pancreatitis: systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol, 2019, 17(6):1061-1072, e8.
[28]	Sano T, Kikuta K, Takikawa T, et al. The M-ANNHEIM-AiP-Activity-Score is useful for predicting relapse in patients with type 1 autoimmune pancreatitis[J]. Pancreatology, 2023, 23(1):112-119.
[29]	de Pretis N, Amodio A, Frulloni L. Updates in the field of autoimmune pancreatitis: a clinical guide[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(7):705-709.
[30]	Hart PA, Levy MJ, Smyrk TC, et al. Clinical profiles and outcomes in idiopathic duct-centric chronic pancreatitis (type 2 autoimmune pancreatitis): the Mayo Clinic experience[J]. Gut, 2016, 65(10):1702-1709.
[31]	Javed AA, Wright MJ, Ding D, et al. Autoimmune pancreatitis: a critical analysis of the surgical experience in an era of modern diagnostics[J]. Pancreas, 2021, 50(4):556-563.
[32]	Meng Q, Xin L, Liu W, et al. Diagnosis and treatment of autoimmune pancreatitis in China: a systematic review[J]. PLoS One, 2015, 10(6):e0130466.
[33]	Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid treatment for autoimmune pancreatitis[J]. Gut, 2009, 58(11):1504-1507.
[34]	Khandelwal A, Inoue D, Takahashi N. Autoimmune pancreatitis: an update[J]. Abdom Radiol, 2020, 45(5):1359-1370.
[35]	徐嘉泽, 胡智明, 杨鸿国, 等. 自身免疫性胰腺炎的诊治进展[J]. 中华普通外科杂志, 2023, 38(1):70-73.
[36]	Tang H, Yang H, Zhang P, et al. Malignancy and IgG4-related disease: the incidence, related factors and prognosis from a prospective cohort study in China[J]. Sci Rep, 2020, 10(1):4910.

Please choose a citation manager

Content to export